Best in Biotech 12 Jun 2023 Six advancements in Alzheimer’s research over the past year …Alzheimer’s. As we observe Alzheimer’s & Brain Awareness Month in June, here are six recent advancements that could transform Alzheimer’s research. Table of contents Coya Therapeutics shows Treg cells can… June 12, 2023 - 12 minutesmins - By Roohi Mariam Peter Share WhatsApp Twitter Linkedin Email
In Depth 26 Oct 2023 Behind closed doors: The unseen controversies and scandals in Alzheimer’s drug trials …on the Alzheimer’s drug industry as a whole. Aduhelm: the first big Alzheimer’s drug controversy of the decade In 2021, Aduhelm – developed by Biogen and Eisai – was granted… October 26, 2023 - 11 minutesmins - By Willow Shah-Neville Share WhatsApp Twitter Linkedin Email
In Depth 15 Feb 2024 Biogen: how is the biotech giant pivoting from a failed Alzheimer’s drug? …Leqembi represents a significant development in Alzheimer’s treatment for both Biogen and the broader Alzheimer’s community. The FDA granted traditional approval to Leqembi for the treatment of Alzheimer’s disease after… February 15, 2024 - 11 minutesmins - By Jules Adam Share WhatsApp Twitter Linkedin Email
In Depth 29 May 2018 Clinical Trials in Alzheimer’s Disease Are Failing: What Can Be Done? …J&J, Eli Lilly and Roche have all failed large phase III trials in Alzheimer’s disease. “It’s the elephant in the room: disease-modifying trials in Alzheimer’s are all failures,” said Niels… May 29, 2018 - 6 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 30 Nov 2022 ‘Best hope yet’ as results from Alzheimer’s drug trial reveal huge step forward …said: “These exciting findings represent a major step forward for dementia research and could herald a new era for people with Alzheimer’s disease. Lecanemab slowing the course of Alzheimer’s “Lecanemab… November 30, 2022 - 6 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 19 Dec 2016 Following Eli Lilly’s Failure, what’s Next in Alzheimer’s Treatments? Hopes for an Alzheimer’s cure took a hit with Eli Lilly’s recent failure, but it’s not over yet. Probiodrug explains the failure and response. Alzheimer’s Disease devastates families and represents… December 19, 2016 - 7 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
Interview 2 Sep 2020 An Alzheimer’s Vaccine Challenged the Consensus for 25 Years …found that pathological forms of tau, rather than amyloid-beta, are indeed the key driver of Alzheimer’s disease. As the amyloid-beta hypothesis has increasingly been challenged, many players in the Alzheimer’s… September 2, 2020 - 8 minutesmins - By Farhan Mitha Share WhatsApp Twitter Linkedin Email
News and Trends 9 Feb 2023 Talking about Alzheimer’s disease: current drugs, clinical trials, and the pipeline …a conversation about current drugs, clinical trials, and the pipeline. What is Alzheimer’s disease? Alzheimer’s is a brain disorder that slowly destroys memory and thinking skills, and, eventually, the ability… February 9, 2023 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jun 2018 Update: Could Epigenetics Treat Alzheimer’s? A Spanish Biotech May Give Us Answers …is not the only biotech who thinks that epigenetics might be a better solution to treating Alzheimer’s. Rodin Therapeutics, in partnership with Biogen, is developing an epigenetic Alzheimer’s treatment targeting… June 25, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 12 Jun 2017 German Biotech Unveils Positive Phase II Results for Alzheimer’s …and now we’re starting to see success.” Probiodrug’s Alzheimer’s pipeline. Drugs like Eli Lilly’s failed solanezumab, or Biogen’s Phase III Alzheimer’s asset aducanumab bind unspecifically to aggregated ABeta, explained Glund…. June 12, 2017 - 3 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 22 Nov 2017 Finnish Scientists Find Brain Cells Involved in Alzheimer’s Disease …relationship between astrocytes and Alzheimer’s using induced pluripotent stem (iPS) cells. These cells can now be investigated as a therapeutic target of future drugs for the neurodegenerative disorder. Alzheimer’s disease… November 22, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
More News! 29 Oct 2018 Plasma Replacement Therapy Promising in Alzheimer’s Patients …496 patients with Alzheimer’s disease in the Phase IIb/III trial. Over 14 months, the therapy had no effect in patients with mild Alzheimer’s, but the therapy successfully slowed cognitive decline… October 29, 2018 - 2 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email